Optimal Tumor Reduction Rate and Modalities for Predicting pCR in Women With Breast Cancer.
Adult
Anthracyclines
/ administration & dosage
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Breast
/ diagnostic imaging
Breast Neoplasms
/ drug therapy
Docetaxel
/ administration & dosage
Drug Administration Schedule
Female
Humans
Magnetic Resonance Imaging
Middle Aged
Neoadjuvant Therapy
Receptor, ErbB-2
/ metabolism
Remission Induction
Trastuzumab
/ administration & dosage
Triple Negative Breast Neoplasms
/ drug therapy
Tumor Burden
/ drug effects
Ultrasonography
Breast cancer
neoadjuvant chemotherapy
predict pCR
Journal
Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
received:
10
02
2020
revised:
04
03
2020
accepted:
05
03
2020
entrez:
3
4
2020
pubmed:
3
4
2020
medline:
21
4
2020
Statut:
ppublish
Résumé
To predict pCR during neoadjuvant chemotherapy is still difficult. The aim of this study was to evaluate the optimal tumor reduction rate and modalities for predicting pCR after two cycles of docetaxel. We analyzed 52 patients with HER2-positive or triple-negative breast cancer. The tumor reduction rate was evaluated after two 3-week cycles of docetaxel (plus trastuzumab for HER2-positive cancer patients). Patients without progression completed two additional cycles of docetaxel and four cycles of an anthracycline-containing regimen. Twenty-eight patients achieved pCR. The optimal tumor reduction rates for predicting pCR were 23, 39, 32, and 40% for US, caliper, MMG, and MRI measurements, respectively. The AUC was highest for caliper measurements. The optimal modality for predicting pCR differed among subtypes. Although tumor reduction rate after two cycles of chemotherapy is highly predictive of pCR, the optimal cutoff value differed among the modalities and breast cancer subtype.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
To predict pCR during neoadjuvant chemotherapy is still difficult. The aim of this study was to evaluate the optimal tumor reduction rate and modalities for predicting pCR after two cycles of docetaxel.
PATIENTS AND METHODS
METHODS
We analyzed 52 patients with HER2-positive or triple-negative breast cancer. The tumor reduction rate was evaluated after two 3-week cycles of docetaxel (plus trastuzumab for HER2-positive cancer patients). Patients without progression completed two additional cycles of docetaxel and four cycles of an anthracycline-containing regimen.
RESULTS
RESULTS
Twenty-eight patients achieved pCR. The optimal tumor reduction rates for predicting pCR were 23, 39, 32, and 40% for US, caliper, MMG, and MRI measurements, respectively. The AUC was highest for caliper measurements. The optimal modality for predicting pCR differed among subtypes.
CONCLUSION
CONCLUSIONS
Although tumor reduction rate after two cycles of chemotherapy is highly predictive of pCR, the optimal cutoff value differed among the modalities and breast cancer subtype.
Identifiants
pubmed: 32234930
pii: 40/4/2303
doi: 10.21873/anticanres.14196
doi:
Substances chimiques
Anthracyclines
0
Docetaxel
15H5577CQD
Receptor, ErbB-2
EC 2.7.10.1
Trastuzumab
P188ANX8CK
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2303-2309Informations de copyright
Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.